<DOC>
	<DOCNO>NCT01250782</DOCNO>
	<brief_summary>Recent report suggest beneficial result glutamine obtain parenteral administration high dos glutamine ( 0.35 g/Kg/d ) special group patient , traumatic patient . Nevertheless total parenteral nutrition often use critically ill patient . The endovenous administration dipeptide N ( 2 ) -L-alanyl-L-glutamine trauma ICU patient reduce number infection , ICU length stay mortality . This benefit achieve independently type nutrition ( enteral parenteral nutrition ) , pharmaconutrient .</brief_summary>
	<brief_title>Effectiveness Dipeptide N ( 2 ) -L-Alanyl-L-Glutamine Trauma ICU Patients : Pilot , Prospective , Randomized Double Blind Study .</brief_title>
	<detailed_description>Objective : To evaluate efficacy endovenous administration endovenous glutamine reduce number infectious complication , mortality ICU length stay trauma ICU patient . To achieve objective design pilot study obtain necessary data design big trial future . Other objective include : - To evaluate efficacy glutamine different patient regard severity : patient Injury Severity Score &gt; 25 patient low plasma level glutamine . - To registry possible adverse event endovenous administration glutamine .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>Moderate severe trauma , define Injury Severity Score ( ISS ) &gt; 10 point include study . Traumatic patient require enteral parenteral nutrition first 48 hour hospital admission Written inform consent patient whose life expectancy le 5 day , allergic glutamine , Patients include trial Cirrhotic patient ( Child C ) Chronic renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Glutamine , trauma patient , infection , mortality</keyword>
</DOC>